Hofer, T.P. et al. Absence of CD4(+) and CD8(+) T cell expansion after primary multimodal treatment predicts early progression in inoperable stage III NSCLC. J. Clin. Oncol. 40:e20590 (2022)
Haffner, I.* et al. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: Results from the prospective multicenter VARIANZ study. J. Clin. Oncol. 39, 1468-1478 (2021)
Burchert, A.* et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J. Clin. Oncol. 38, 2993-3002 (2020)
Aubele, M. et al. uPA receptor and its interaction partners: Impact as potential therapeutic targets in triple-negative breast cancer. J. Clin. Oncol. 33:150 (2015)
Pastore, F. et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J. Clin. Oncol. 32, 1586-1594 (2014)
Icheva, V.* et al. Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J. Clin. Oncol. 31, 5-7 (2013)
Icheva, V.* et al. Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J. Clin. Oncol. 31, 39-48 (2013)
Li, Z.* et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: An international collaborative study. J. Clin. Oncol. 31, 1172-1181 (2013)
Buck, K.* et al. Serum enterolactone and prognosis of postmenopausal breast cancer. J. Clin. Oncol. 29, 3730-3738 (2011)
Dufour, A.* et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J. Clin. Oncol. 28, 570-577 (2010)
Gires, O. & Bauerle, P.A.* EpCAM as a target in cancer therapy. J. Clin. Oncol. 28, E239-E240 (2010)
Metzeler, K.H. et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: A comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J. Clin. Oncol. 27, 5031-5038 (2009)
van Glabbeke, M.* & Schlemmer, M. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J. Clin. Oncol. 23, 5795-5804 (2005)
Wendtner, C.-M.* et al. Response to Neoadjuvant Chemotherapy Combined with Regional Hyperthermia Predicts Long-Term Survival for Adult Patients with Retroperitoneal and Visceral High-Risk Soft Tissue Sarcomas.  J. Clin. Oncol. 20, 3156-3164 (2002)
Issels, R.D. et al. Ifosfamide Plus Etoposide Combined with Regional Hyperthermia in Patients with Locally  Advanced Sarcomas: A Phase II Study. J. Clin. Oncol. (1990)